BioAlliance Pharma announces extension of Loramyc® approval in 13 European countries

It is bringing total European approvals to 26 European countries

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announced today the approval of Loramyc® in 13 additional European countries* through a Mutual Recognition Procedure with France as reference member state.
With this approval to a total of 26 European countries for Loramyc® and the recent Setofilm® ** approval in 16 European countries, BioAlliance is building an attractive cancer supportive care portfolio including this two complementary products.
“These remarkable achievements for both Loramyc® and Setofilm® demonstrate BioAlliance Pharma’s expertise and the dedication of its teams. They will contribute to our commercial success in Europe”, said Dominique Costantini, President and CEO of BioAlliance Pharma.
* Recent Loramyc® approvals: Austria, Bulgaria, Czech Republic, Estonia, Greece, Hungary, Letonia, Lithuania, Poland, Portugal, Romania, Slovak Republic, Slovenia.
Initial Loramyc® approvals: Belgium, Germany, Denmark, Finland, France, Italy, Luxemburg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom.
**Setofilm®: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxemburg, Netherlands, Norway, Portugal, Spain, Sweden, UK.

100325EN_Loramyc_2evague (2)